PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.23
Negative OCF/share while Healthcare median is -0.03. Seth Klarman would examine if a turnaround is realistic.
-0.23
Negative FCF/share while Healthcare median is -0.07. Seth Klarman would question if the business is too capex-heavy.
No Data
No Data available this quarter, please select a different quarter.
0.63
Ratio 0.75–0.9x Healthcare median of 0.74. John Neff would push for improved working capital or cost management.
-21965.22%
Negative ratio while Healthcare median is 0.00%. Seth Klarman would suspect deeper operational issues or near-zero revenue.